课题基金 / 基金详情

Optimization of enrichment for MALDI TOF/TOF identification of cancer biomarkers

Optimization of enrichment for MALDI TOF/TOF identification of cancer biomarkers
癌症生物标志物 MALDI TOF/TOF 鉴定的富集优化
批准号:
7151111
负责人:
RADOSLAV GOLDMAN
金额:
$7.76万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-13 至 2008-06-30

项目摘要

项目成果

RADOSLAV GOLDMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Early detection of cancer and precancerous conditions improves patient survival. This study optimizes methods for discovery of a diagnostic set of peptides and proteins (P/P) in serum of patients with hepatocellular carcinoma (HCC). To identify biomarkers of HCC, we developed enrichment of low molecular weight (LMW) fraction of serum for matrix assisted laser desorption ionization-time of flight (MALDI- TOF/TOF) mass spectrometry (MS). This method allows high-throughput population screening as well as identification of the peptides of interest by TOF/TOF sequencing. We tested the biomarker discovery method on a pilot set of HCC cases and matched controls, which identified a set of P/P predictive of HCC with greater than 90% prediction accuracy. In this study, we propose to adjust the method to complementary enrichment using WCX and Cu-IMAC magnetic beads, expand the study to include a comparison with premalignant liver disease (150 cases, 150 matched controls, 50 cirrhosis), and to begin identification of the biomarker-candidates by sequencing. The samples come from our ongoing case-control study of HCC in Egypt, a country with an epidemic of hepatitis C infection and HCC. Our goal is to identify biomarkers that would improved early detection of HCC and track the natural progression of chronic viral infection to cancer. The identity of the biomarkers will be verified by MALDI-TOF/TOF sequencing and complementary liquid chromatography/mass spectrometry methods. Defining clinically applicable biomarkers of early-stage cancer has potentially far-reaching consequences for disease management and patient health. The biomarkers could be used to screen high risk populations for early signs of disease; to design and test improved chemoprevention strategies; and to follow disease progression after treatment. Identification of the P/P is expected to generate new hypotheses for targeted disease management.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
timsTOF Pro Mass Spectrometer
  • 批准号:
    10173053
  • 项目类别:
  • 资助金额:
    $60.0万
  • 财政年份:
    2021
  • 负责人:
    RADOSLAV GOLDMAN
  • 依托单位:
O-glycoproteins in the progression of liver disease
  • 批准号:
    9920111
  • 项目类别:
  • 资助金额:
    $51.53万
  • 财政年份:
    2019
  • 负责人:
    RADOSLAV GOLDMAN
  • 依托单位:
O-glycoproteins in the progression of liver disease
  • 批准号:
    10206066
  • 项目类别:
  • 资助金额:
    $51.53万
  • 财政年份:
    2019
  • 负责人:
    RADOSLAV GOLDMAN
  • 依托单位:
O-glycoproteins in the progression of liver disease
  • 批准号:
    10450085
  • 项目类别:
  • 资助金额:
    $50.5万
  • 财政年份:
    2019
  • 负责人:
    RADOSLAV GOLDMAN
  • 依托单位:
海外基金